標(biāo)題: Titlebook: Diagnosis and Management of Testicular Cancer; The European Point o Susanne Krege Book 2015 Springer International Publishing Switzerland 2 [打印本頁] 作者: Iodine 時間: 2025-3-21 18:53
書目名稱Diagnosis and Management of Testicular Cancer影響因子(影響力)
書目名稱Diagnosis and Management of Testicular Cancer影響因子(影響力)學(xué)科排名
書目名稱Diagnosis and Management of Testicular Cancer網(wǎng)絡(luò)公開度
書目名稱Diagnosis and Management of Testicular Cancer網(wǎng)絡(luò)公開度學(xué)科排名
書目名稱Diagnosis and Management of Testicular Cancer被引頻次
書目名稱Diagnosis and Management of Testicular Cancer被引頻次學(xué)科排名
書目名稱Diagnosis and Management of Testicular Cancer年度引用
書目名稱Diagnosis and Management of Testicular Cancer年度引用學(xué)科排名
書目名稱Diagnosis and Management of Testicular Cancer讀者反饋
書目名稱Diagnosis and Management of Testicular Cancer讀者反饋學(xué)科排名
作者: 內(nèi)行 時間: 2025-3-21 22:49 作者: 教義 時間: 2025-3-22 03:14 作者: grounded 時間: 2025-3-22 06:38 作者: Latency 時間: 2025-3-22 09:54 作者: 整潔漂亮 時間: 2025-3-22 12:55 作者: 整潔漂亮 時間: 2025-3-22 18:35 作者: MIR 時間: 2025-3-22 22:52 作者: 泰然自若 時間: 2025-3-23 03:12 作者: 從容 時間: 2025-3-23 08:06
https://doi.org/10.1007/978-1-4842-9830-5ures such as the kidney, the aorta, inferior vena cava or vertebral bodies. The surgeon has to identify these lesions preoperatively and it mandatory to develop an interdisciplinary approach. Postchemotherapy surgeries should be done in tertiary referral centres only.作者: Narrative 時間: 2025-3-23 12:42
Book 2015the field. It opens by providing an overview of the recommendations in the most recent consensus paper from the European Germ Cell Cancer Consensus Group, which is based on interdisciplinary cooperation among urologists, medical oncologists, radio-oncologists, pathologists, and basic scientists. The作者: CURB 時間: 2025-3-23 14:07
Latest Recommendations of the European Germ Cell Cancer Group on Diagnosis and Treatment of Germ Cele et al. Eur Urol 53:497–513, 2008), the latest published in 2012 (Beyer et al. Ann Oncol 24:878–888, 2013). In this chapter, the recent recommendations of the European group are summarized. The following chapters will present some topics in detail, which are still discussed controversial, or for which the best management is not yet found.作者: Innocence 時間: 2025-3-23 20:03
How Should Patients with Recurrent Disease Be Treated Actually?of HDCT as first-line salvage therapy in relapsed patients with highly favorable risk profiles. In order to avoid overtreatment, HDCT should only be administered at specialist centres with the necessary expertise.作者: PLIC 時間: 2025-3-23 23:23
Prognostic Factors at Initial Presentation and in Recurrent Diseaseisease. This discussion has been presented in the previous chapters of this book. The other one will be presented here and focuses on the much more pressing question of survival probabilities in patients with metastatic disease.作者: Anemia 時間: 2025-3-24 06:26
https://doi.org/10.1007/978-1-4842-9830-5 follow-up has to be tailored to each individual patient, and the schedule has to be acceptable for the patient, the physician, as well as the health-care system [2]. The interval of follow-up visits and the tests to be performed at each visit depend on the risk of relapse in general and on the likely site of relapse in particular [2, 3].作者: ALLEY 時間: 2025-3-24 09:42 作者: Robust 時間: 2025-3-24 13:05 作者: consolidate 時間: 2025-3-24 14:54 作者: NEX 時間: 2025-3-24 22:42 作者: NOT 時間: 2025-3-25 01:06
https://doi.org/10.1007/978-1-4842-9830-5isease. This discussion has been presented in the previous chapters of this book. The other one will be presented here and focuses on the much more pressing question of survival probabilities in patients with metastatic disease.作者: 江湖騙子 時間: 2025-3-25 03:52 作者: agitate 時間: 2025-3-25 11:13 作者: 指數(shù) 時間: 2025-3-25 12:47 作者: 圓桶 時間: 2025-3-25 19:02
https://doi.org/10.1007/978-1-4842-9830-5ying from recurrent TC or a second cancer, TCS have a 6 % increased risk of mortality from non-cancer causes, including infections, cardiovascular disease (CVD), and respiratory disease after cisplatin-based chemotherapy compared with the general population [2].作者: 討人喜歡 時間: 2025-3-25 20:56
Latest Recommendations of the European Germ Cell Cancer Group on Diagnosis and Treatment of Germ Cel9, 2004). The consensus group consisted of more than 60 experts from all across Europe. The experts involved were oncologists, urologic surgeons, radiooncologists, pathologists and basic scientists. Since then, regular updates were performed by the group (Krege et al. Eur Urol 53:478–496, 2008; Kreg作者: 甜食 時間: 2025-3-26 03:41 作者: Cabinet 時間: 2025-3-26 07:50
Is There Still an Indication for Primary RPLND in Clinical Stage I Non-seminoma? A significant proportion (about two thirds) of patients with ascertained small nodal metastases at RPLND, are cured by surgery with no need of further therapy..The introduction of effective cisplatin-based chemotherapy has progressively reduced the role of primary RPLND in early stages NSGCT. This 作者: Alopecia-Areata 時間: 2025-3-26 12:28 作者: 傻瓜 時間: 2025-3-26 12:37
Poor-Prognosis Germ Cell TumoursCT, extra-pulmonary visceral metastases or very high serum tumour marker levels (hCG > 50,000 UI/L, AFP > 10,000 ng/mL and/or LDH > 10 times the upper limit value). This subgroup of 10% patients is responsible for most of the deaths from GCT. Their progression-free survival rate is 41 % with only ha作者: VEN 時間: 2025-3-26 18:59 作者: Alveolar-Bone 時間: 2025-3-26 22:07
Prognostic Factors at Initial Presentation and in Recurrent Diseases well as to compare treatment results across different institutions. The issue of prognostic factors can be divided into two broad categories. One focuses on the use of prognostic factors in clinical stage I seminoma and non-seminoma in order to assess a patient’s risk of having occult metastatic d作者: 廣大 時間: 2025-3-27 03:48 作者: hyperuricemia 時間: 2025-3-27 07:59
What Are the Recent Recommendations for Follow-Up in Testicular Cancer?(adjuvant therapy or curative treatment of advanced disease), is an important part of the management of this disease. The primary aim of follow-up is the timely diagnosis of recurrent disease in order to be able to treat the patient with curative intent with the least aggressive therapy [1]. An adeq作者: 狂熱文化 時間: 2025-3-27 13:03 作者: AGOG 時間: 2025-3-27 15:30
Consequences of the Disease and Its Treatment Concerning Sexuality and Fertilitypart from late toxicity affecting general health by either vascular, neuropathic, nephrotoxic or ototoxic side effects or by inducing second malignancies, fertility and sexuality are negatively affected. Gonadal function is essential for fertility and normal endocrine profile. Both the disease itsel作者: Entirety 時間: 2025-3-27 18:54 作者: 不妥協(xié) 時間: 2025-3-27 22:30
http://image.papertrans.cn/d/image/270582.jpg作者: LINES 時間: 2025-3-28 05:17 作者: FORGO 時間: 2025-3-28 07:46
978-3-319-35963-2Springer International Publishing Switzerland 2015作者: MOAT 時間: 2025-3-28 10:58
Is There Still an Indication for Radiotherapy in Seminoma Clinical Stages I–IIA/B?ed second cancer. Adjuvant chemotherapy with carboplatin or active surveillance represents effective alternative therapeutic options in stage I. For patients with limited stage II, radiotherapy may be considered though cisplatin-based chemotherapy is the treatment preferred by most European clinicians.作者: 大氣層 時間: 2025-3-28 15:11 作者: disrupt 時間: 2025-3-28 21:35
Truss: A Standard Verification Framework9, 2004). The consensus group consisted of more than 60 experts from all across Europe. The experts involved were oncologists, urologic surgeons, radiooncologists, pathologists and basic scientists. Since then, regular updates were performed by the group (Krege et al. Eur Urol 53:478–496, 2008; Kreg作者: Flatus 時間: 2025-3-29 01:08
https://doi.org/10.1007/978-0-387-71740-1ed second cancer. Adjuvant chemotherapy with carboplatin or active surveillance represents effective alternative therapeutic options in stage I. For patients with limited stage II, radiotherapy may be considered though cisplatin-based chemotherapy is the treatment preferred by most European clinicia作者: 豐富 時間: 2025-3-29 04:13
Hardware Verification with System Verilog A significant proportion (about two thirds) of patients with ascertained small nodal metastases at RPLND, are cured by surgery with no need of further therapy..The introduction of effective cisplatin-based chemotherapy has progressively reduced the role of primary RPLND in early stages NSGCT. This 作者: CHOP 時間: 2025-3-29 09:54 作者: 和平 時間: 2025-3-29 12:33 作者: 甜得發(fā)膩 時間: 2025-3-29 15:49 作者: BRIEF 時間: 2025-3-29 23:42
https://doi.org/10.1007/978-1-4842-9830-5s well as to compare treatment results across different institutions. The issue of prognostic factors can be divided into two broad categories. One focuses on the use of prognostic factors in clinical stage I seminoma and non-seminoma in order to assess a patient’s risk of having occult metastatic d作者: ETHER 時間: 2025-3-30 02:37
https://doi.org/10.1007/978-1-4842-9830-5 cancer. The reationale to resect residual masses is due to the fact that about 30–40 % and 10 % of patients harbour teratoma and vital cancer, respectively, in the residual masses. Resection of these masses is done with a curative intent so that it is mandatory to resect all masses independent on t
